{
    "organizations": [],
    "uuid": "fb7fb154358923e84c77fdc30b0f371b5603cfab",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-astrazeneca-says-selumetinib-in-nf/brief-astrazeneca-says-selumetinib-in-nf1-gets-fda-orphan-drug-status-idUSFWN1Q50DX",
    "ord_in_thread": 0,
    "title": "BRIEF-Astrazeneca Says ‍Selumetinib In Nf1 Gets FDA Orphan Drug Status​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 15 (Reuters) - Astrazeneca Plc:\n* ‍SELUMETINIB IN NF1 GETS FDA ORPHAN DRUG STATUS​ * US FDA GRANTED ORPHAN DRUG DESIGNATION (ODD) FOR SELUMETINIB, A MEK 1/2 INHIBITOR, FOR TREATMENT OF NEUROFIBROMATOSIS TYPE 1 (NF1)​\n* ‍SELUMETINIB IN NF1 GETS FDA ORPHAN DRUG STATUS​ * ‍PHASE II TRIAL RESULTS ARE EXPECTED LATER IN 2018​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)\n ",
    "published": "2018-02-15T15:29:00.000+02:00",
    "crawled": "2018-02-16T16:38:56.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "astrazeneca",
        "plc",
        "nf1",
        "get",
        "fda",
        "orphan",
        "drug",
        "u",
        "fda",
        "granted",
        "orphan",
        "drug",
        "designation",
        "odd",
        "selumetinib",
        "mek",
        "inhibitor",
        "treatment",
        "neurofibromatosis",
        "type",
        "nf1",
        "nf1",
        "get",
        "fda",
        "orphan",
        "drug",
        "ii",
        "trial",
        "result",
        "expected",
        "later",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}